NASACORT ALLERGY 24 HOUR Drug Patent Profile
✉ Email this page to a colleague
When do Nasacort Allergy 24 Hour patents expire, and when can generic versions of Nasacort Allergy 24 Hour launch?
Nasacort Allergy 24 Hour is a drug marketed by Chattem Sanofi and is included in one NDA.
The generic ingredient in NASACORT ALLERGY 24 HOUR is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nasacort Allergy 24 Hour
A generic version of NASACORT ALLERGY 24 HOUR was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1st, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NASACORT ALLERGY 24 HOUR?
- What are the global sales for NASACORT ALLERGY 24 HOUR?
- What is Average Wholesale Price for NASACORT ALLERGY 24 HOUR?
Summary for NASACORT ALLERGY 24 HOUR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,868 |
| DailyMed Link: | NASACORT ALLERGY 24 HOUR at DailyMed |
Recent Clinical Trials for NASACORT ALLERGY 24 HOUR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gail Gauvreau | N/A |
| Stanford University | Phase 4 |
| Sanofi | Phase 4 |
Pharmacology for NASACORT ALLERGY 24 HOUR
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for NASACORT ALLERGY 24 HOUR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NASACORT ALLERGY 24 HOUR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Chattem Sanofi | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | 5,976,573 | ⤷ Start Trial |
| Chattem Sanofi | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | 7,977,045 | ⤷ Start Trial |
| Chattem Sanofi | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | 6,143,329 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NASACORT ALLERGY 24 HOUR
See the table below for patents covering NASACORT ALLERGY 24 HOUR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1045 | Aqueous pharmaceutical composition capable of being sprayed into nasal cavity. | ⤷ Start Trial |
| African Regional IP Organization (ARIPO) | 9901495 | ⤷ Start Trial | |
| Austria | 250432 | ⤷ Start Trial | |
| Australia | 3647197 | ⤷ Start Trial | |
| Australia | 737506 | ⤷ Start Trial | |
| Bulgaria | 103127 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch